pstat1 y701 24 h cell signaling ab Search Results


htb 15 j cells  (ATCC)
96
ATCC htb 15 j cells
Depletion of VAMP8 impairs STAT1 phosphorylation downstream of IFN-I signaling but does not alter WNV replication. (A and B) wt A549 cells were treated with nontargeting control (control) or VAMP8-targeting (VAMP8) siRNAs for 24 h, followed by infection with WNV 385-99 (MOI of 0.1) for 72 h. Supernatants and lysates of infected cells were collected at 1, 6, 24, 48, and 72 h p.i. to assess viral loads by plaque assays (A) and protein expression and phosphorylation by Western blotting (B). (C and D) The bands in the Western blot were quantified by densitometry as described in the legend of Fig. 1. (E to J) wt A549 (E to I) or ATCC HTB-15 (J) cells were treated with nontargeting control (siControl) or VAMP8-targeting (siVAMP8) siRNAs for 24 h, followed by treatment with recombinant human IFN-β-1a (500 U/ml) (E, F, I, and J) or human IFN-γ (500 U/ml) (G and H). IFN treatments shown in panels E, F, I, and J were done for 16 h. Cells were lysed, and either protein (E to H) or RNA (I and J) was isolated for analysis by Western blotting or qRT-PCR, respectively. Error bars represent standard deviations. Gene expression data were analyzed using one-way ANOVA with Tukey’s posttest to assess statistical significance (I and J) (****, P < 0.0001; **, P < 0.01. No statistical significance was found in panel A. The experiment was performed in triplicate.
Htb 15 J Cells, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/htb 15 j cells/product/ATCC
Average 96 stars, based on 1 article reviews
htb 15 j cells - by Bioz Stars, 2026-03
96/100 stars
  Buy from Supplier
pstat1 y701 24 h cell signaling ab  (Cell Signaling Technology Inc)
99
Cell Signaling Technology Inc pstat1 y701 24 h cell signaling ab
Depletion of VAMP8 impairs STAT1 phosphorylation downstream of IFN-I signaling but does not alter WNV replication. (A and B) wt A549 cells were treated with nontargeting control (control) or VAMP8-targeting (VAMP8) siRNAs for 24 h, followed by infection with WNV 385-99 (MOI of 0.1) for 72 h. Supernatants and lysates of infected cells were collected at 1, 6, 24, 48, and 72 h p.i. to assess viral loads by plaque assays (A) and protein expression and phosphorylation by Western blotting (B). (C and D) The bands in the Western blot were quantified by densitometry as described in the legend of Fig. 1. (E to J) wt A549 (E to I) or ATCC HTB-15 (J) cells were treated with nontargeting control (siControl) or VAMP8-targeting (siVAMP8) siRNAs for 24 h, followed by treatment with recombinant human IFN-β-1a (500 U/ml) (E, F, I, and J) or human IFN-γ (500 U/ml) (G and H). IFN treatments shown in panels E, F, I, and J were done for 16 h. Cells were lysed, and either protein (E to H) or RNA (I and J) was isolated for analysis by Western blotting or qRT-PCR, respectively. Error bars represent standard deviations. Gene expression data were analyzed using one-way ANOVA with Tukey’s posttest to assess statistical significance (I and J) (****, P < 0.0001; **, P < 0.01. No statistical significance was found in panel A. The experiment was performed in triplicate.
Pstat1 Y701 24 H Cell Signaling Ab, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/pstat1 y701 24 h cell signaling ab/product/Cell Signaling Technology Inc
Average 99 stars, based on 1 article reviews
pstat1 y701 24 h cell signaling ab - by Bioz Stars, 2026-03
99/100 stars
  Buy from Supplier
total stat1  (Cell Signaling Technology Inc)
90
Cell Signaling Technology Inc total stat1
Depletion of VAMP8 impairs STAT1 phosphorylation downstream of IFN-I signaling but does not alter WNV replication. (A and B) wt A549 cells were treated with nontargeting control (control) or VAMP8-targeting (VAMP8) siRNAs for 24 h, followed by infection with WNV 385-99 (MOI of 0.1) for 72 h. Supernatants and lysates of infected cells were collected at 1, 6, 24, 48, and 72 h p.i. to assess viral loads by plaque assays (A) and protein expression and phosphorylation by Western blotting (B). (C and D) The bands in the Western blot were quantified by densitometry as described in the legend of Fig. 1. (E to J) wt A549 (E to I) or ATCC HTB-15 (J) cells were treated with nontargeting control (siControl) or VAMP8-targeting (siVAMP8) siRNAs for 24 h, followed by treatment with recombinant human IFN-β-1a (500 U/ml) (E, F, I, and J) or human IFN-γ (500 U/ml) (G and H). IFN treatments shown in panels E, F, I, and J were done for 16 h. Cells were lysed, and either protein (E to H) or RNA (I and J) was isolated for analysis by Western blotting or qRT-PCR, respectively. Error bars represent standard deviations. Gene expression data were analyzed using one-way ANOVA with Tukey’s posttest to assess statistical significance (I and J) (****, P < 0.0001; **, P < 0.01. No statistical significance was found in panel A. The experiment was performed in triplicate.
Total Stat1, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/total stat1/product/Cell Signaling Technology Inc
Average 90 stars, based on 1 article reviews
total stat1 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
anti pstat1  (Abcam)
95
Abcam anti pstat1
Depletion of VAMP8 impairs STAT1 phosphorylation downstream of IFN-I signaling but does not alter WNV replication. (A and B) wt A549 cells were treated with nontargeting control (control) or VAMP8-targeting (VAMP8) siRNAs for 24 h, followed by infection with WNV 385-99 (MOI of 0.1) for 72 h. Supernatants and lysates of infected cells were collected at 1, 6, 24, 48, and 72 h p.i. to assess viral loads by plaque assays (A) and protein expression and phosphorylation by Western blotting (B). (C and D) The bands in the Western blot were quantified by densitometry as described in the legend of Fig. 1. (E to J) wt A549 (E to I) or ATCC HTB-15 (J) cells were treated with nontargeting control (siControl) or VAMP8-targeting (siVAMP8) siRNAs for 24 h, followed by treatment with recombinant human IFN-β-1a (500 U/ml) (E, F, I, and J) or human IFN-γ (500 U/ml) (G and H). IFN treatments shown in panels E, F, I, and J were done for 16 h. Cells were lysed, and either protein (E to H) or RNA (I and J) was isolated for analysis by Western blotting or qRT-PCR, respectively. Error bars represent standard deviations. Gene expression data were analyzed using one-way ANOVA with Tukey’s posttest to assess statistical significance (I and J) (****, P < 0.0001; **, P < 0.01. No statistical significance was found in panel A. The experiment was performed in triplicate.
Anti Pstat1, supplied by Abcam, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti pstat1/product/Abcam
Average 95 stars, based on 1 article reviews
anti pstat1 - by Bioz Stars, 2026-03
95/100 stars
  Buy from Supplier
anti-ki67 antibody  (Thermo Fisher)
90
Thermo Fisher anti-ki67 antibody
Depletion of VAMP8 impairs STAT1 phosphorylation downstream of IFN-I signaling but does not alter WNV replication. (A and B) wt A549 cells were treated with nontargeting control (control) or VAMP8-targeting (VAMP8) siRNAs for 24 h, followed by infection with WNV 385-99 (MOI of 0.1) for 72 h. Supernatants and lysates of infected cells were collected at 1, 6, 24, 48, and 72 h p.i. to assess viral loads by plaque assays (A) and protein expression and phosphorylation by Western blotting (B). (C and D) The bands in the Western blot were quantified by densitometry as described in the legend of Fig. 1. (E to J) wt A549 (E to I) or ATCC HTB-15 (J) cells were treated with nontargeting control (siControl) or VAMP8-targeting (siVAMP8) siRNAs for 24 h, followed by treatment with recombinant human IFN-β-1a (500 U/ml) (E, F, I, and J) or human IFN-γ (500 U/ml) (G and H). IFN treatments shown in panels E, F, I, and J were done for 16 h. Cells were lysed, and either protein (E to H) or RNA (I and J) was isolated for analysis by Western blotting or qRT-PCR, respectively. Error bars represent standard deviations. Gene expression data were analyzed using one-way ANOVA with Tukey’s posttest to assess statistical significance (I and J) (****, P < 0.0001; **, P < 0.01. No statistical significance was found in panel A. The experiment was performed in triplicate.
Anti Ki67 Antibody, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti-ki67 antibody/product/Thermo Fisher
Average 90 stars, based on 1 article reviews
anti-ki67 antibody - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

Image Search Results


Depletion of VAMP8 impairs STAT1 phosphorylation downstream of IFN-I signaling but does not alter WNV replication. (A and B) wt A549 cells were treated with nontargeting control (control) or VAMP8-targeting (VAMP8) siRNAs for 24 h, followed by infection with WNV 385-99 (MOI of 0.1) for 72 h. Supernatants and lysates of infected cells were collected at 1, 6, 24, 48, and 72 h p.i. to assess viral loads by plaque assays (A) and protein expression and phosphorylation by Western blotting (B). (C and D) The bands in the Western blot were quantified by densitometry as described in the legend of Fig. 1. (E to J) wt A549 (E to I) or ATCC HTB-15 (J) cells were treated with nontargeting control (siControl) or VAMP8-targeting (siVAMP8) siRNAs for 24 h, followed by treatment with recombinant human IFN-β-1a (500 U/ml) (E, F, I, and J) or human IFN-γ (500 U/ml) (G and H). IFN treatments shown in panels E, F, I, and J were done for 16 h. Cells were lysed, and either protein (E to H) or RNA (I and J) was isolated for analysis by Western blotting or qRT-PCR, respectively. Error bars represent standard deviations. Gene expression data were analyzed using one-way ANOVA with Tukey’s posttest to assess statistical significance (I and J) (****, P < 0.0001; **, P < 0.01. No statistical significance was found in panel A. The experiment was performed in triplicate.

Journal: Journal of Virology

Article Title: VAMP8 Contributes to the TRIM6-Mediated Type I Interferon Antiviral Response during West Nile Virus Infection

doi: 10.1128/JVI.01454-19

Figure Lengend Snippet: Depletion of VAMP8 impairs STAT1 phosphorylation downstream of IFN-I signaling but does not alter WNV replication. (A and B) wt A549 cells were treated with nontargeting control (control) or VAMP8-targeting (VAMP8) siRNAs for 24 h, followed by infection with WNV 385-99 (MOI of 0.1) for 72 h. Supernatants and lysates of infected cells were collected at 1, 6, 24, 48, and 72 h p.i. to assess viral loads by plaque assays (A) and protein expression and phosphorylation by Western blotting (B). (C and D) The bands in the Western blot were quantified by densitometry as described in the legend of Fig. 1. (E to J) wt A549 (E to I) or ATCC HTB-15 (J) cells were treated with nontargeting control (siControl) or VAMP8-targeting (siVAMP8) siRNAs for 24 h, followed by treatment with recombinant human IFN-β-1a (500 U/ml) (E, F, I, and J) or human IFN-γ (500 U/ml) (G and H). IFN treatments shown in panels E, F, I, and J were done for 16 h. Cells were lysed, and either protein (E to H) or RNA (I and J) was isolated for analysis by Western blotting or qRT-PCR, respectively. Error bars represent standard deviations. Gene expression data were analyzed using one-way ANOVA with Tukey’s posttest to assess statistical significance (I and J) (****, P < 0.0001; **, P < 0.01. No statistical significance was found in panel A. The experiment was performed in triplicate.

Article Snippet: In contrast, the amount of pSTAT1 (Y701) was notably smaller in the VAMP8-kd cells, suggesting impairment in the IFN-I signaling pathway ( and ). fig ft0 fig mode=article f1 fig/graphic|fig/alternatives/graphic mode="anchored" m1 Open in a separate window FIG 4 caption a7 Depletion of VAMP8 impairs STAT1 phosphorylation downstream of IFN-I signaling but does not alter WNV replication. (A and B) wt A549 cells were treated with nontargeting control (control) or VAMP8-targeting (VAMP8) siRNAs for 24 h, followed by infection with WNV 385-99 (MOI of 0.1) for 72 h. Supernatants and lysates of infected cells were collected at 1, 6, 24, 48, and 72 h p.i. to assess viral loads by plaque assays (A) and protein expression and phosphorylation by Western blotting (B). (C and D) The bands in the Western blot were quantified by densitometry as described in the legend of . (E to J) wt A549 (E to I) or ATCC HTB-15 (J) cells were treated with nontargeting control (siControl) or VAMP8-targeting (siVAMP8) siRNAs for 24 h, followed by treatment with recombinant human IFN-β-1a (500 U/ml) (E, F, I, and J) or human IFN-γ (500 U/ml) (G and H).

Techniques: Infection, Expressing, Western Blot, Recombinant, Isolation, Quantitative RT-PCR